Westfield Capital Management Co. LP Acquires 34,188 Shares of Omnicell, Inc. (OMCL)
Westfield Capital Management Co. LP grew its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 3.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 959,432 shares of the company’s stock after purchasing an additional 34,188 shares during the period. Westfield Capital Management Co. LP owned approximately 2.58% of Omnicell worth $41,352,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in OMCL. Ameritas Investment Partners Inc. purchased a new position in shares of Omnicell during the first quarter valued at approximately $125,000. LS Investment Advisors LLC lifted its holdings in shares of Omnicell by 136.3% during the first quarter. LS Investment Advisors LLC now owns 3,571 shares of the company’s stock valued at $145,000 after purchasing an additional 2,060 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new position in shares of Omnicell during the first quarter valued at approximately $170,000. Turner Investments LLC purchased a new position in shares of Omnicell during the second quarter valued at approximately $181,000. Finally, Riverhead Capital Management LLC lifted its holdings in shares of Omnicell by 76.3% during the second quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock valued at $182,000 after purchasing an additional 1,830 shares during the last quarter. Hedge funds and other institutional investors own 96.35% of the company’s stock.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Benchmark Co. lifted their target price on shares of Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday, September 5th. BidaskClub lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. ValuEngine raised shares of Omnicell from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $40.00 price target on shares of Omnicell in a research report on Sunday, July 30th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Omnicell has a consensus rating of “Buy” and an average target price of $51.57.
Shares of Omnicell, Inc. (NASDAQ OMCL) traded down 1.11% during midday trading on Friday, hitting $49.10. 473,758 shares of the company traded hands. The company has a 50-day moving average price of $50.08 and a 200-day moving average price of $43.42. Omnicell, Inc. has a 52 week low of $30.35 and a 52 week high of $52.70. The stock’s market capitalization is $1.84 billion.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.02. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The company had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.08 million. During the same quarter in the prior year, the company posted $0.38 earnings per share. Omnicell’s revenue for the quarter was up 4.6% compared to the same quarter last year. Analysts anticipate that Omnicell, Inc. will post $1.30 earnings per share for the current fiscal year.
In related news, EVP Robin Gene Seim sold 9,780 shares of the stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $48.97, for a total transaction of $478,926.60. Following the completion of the sale, the executive vice president now owns 55,896 shares of the company’s stock, valued at $2,737,227.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Randall A. Lipps sold 10,625 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $52.00, for a total transaction of $552,500.00. The disclosure for this sale can be found here. Insiders have sold 212,089 shares of company stock valued at $10,266,363 in the last three months. 3.77% of the stock is currently owned by corporate insiders.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.